ViiV's fostemsavir maintains virologic suppression at week 48 in Phase III for HIV

ViiV Healthcare Ltd. (Brentford, U.K.) said fostemsavir plus optimized background therapy maintained virologic suppression of less than 40 copies/mL from week 24 to 48 in 54% of heavily treatment-experienced patients with HIV-1 infection in the randomized cohort (n=272) of the Phase III BRIGHTE trial. Fostemsavir plus optimized background therapy also increased mean CD4+ T cell counts from baseline by 139 cells/μL at week 48.

The double-blind, international trial enrolled 371 patients who failed antiretroviral agents in at least four of the six available antiretroviral classes and separated patients into a randomized and non-randomized cohort. Last year, ViiV said fostemsavir as an add-on to the patient's current failing regimen met the primary endpoint of reducing mean HIV-1 viral load from baseline to day eight vs. placebo in the trial's randomized cohort (0.79 vs. 0.17 log10 copies/mL, p<0.0001) (see "ViiV's HIV Candidate Fostemsavir Meets in Phase III")...